IRLA — IRulya Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662774 ·
Last close
$32.03
Market Cap
—
52W High
$910.00
52W Low
$15.10
ADV30
30,203
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -22,087,000 | -75,488,000 | 123,995,000 | 115,981,000 | 159,320,000 |
| Mar 2026 | 0 | — | -11,112,000 | 35,912,000 | 26,623,000 | 18,163,000 | 10,951,000 |
| Dec 2025 | 0 | — | -16,236,000 | -39,458,000 | 93,523,000 | 5,809,000 | 129,237,000 |
| Sep 2025 | 0 | — | -11,364,000 | -13,442,000 | 109,899,000 | 6,452,000 | 108,840,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,923,000
Investing CF
$26,291,000
Financing CF
$121,786,000
CapEx
$-352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-73.46
As of
2026-10-17
Balance + Analyst (yfinance extras)
Retained Earnings
$-500,027,000
Inventory
—
Receivables
$5,002,000
ST Investments
$0
EBIT TTM
$-60,799,000
Pretax Income TTM
$-94,640,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -50,429,000 | -83,979,000 | 93,523,000 | 129,237,000 | -35,714,000 | -41,425,000 |
| Dec 2024 | 0 | -36,170,000 | -56,828,000 | 114,478,000 | 84,332,000 | 30,146,000 | -31,904,000 |
| Dec 2023 | 0 | -27,142,000 | -31,385,000 | 167,900,000 | 82,816,000 | 85,084,000 | -18,292,000 |
| Dec 2022 | 0 | -51,190,000 | -51,660,000 | 103,910,000 | 3,317,000 | 100,593,000 | -44,038,000 |
TTM Snapshot
Revenues TTM
$1,271,000
NetIncome TTM
$-92,476,000
OpCashFlow TTM
—
Assets (Latest)
$123,995,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $233.82B | $432.49 | — |
| GILD | GILEAD SCIENCES, INC. | $193.67B | $156.19 | — |
| MRNA | Moderna, Inc. | $87.04B | $218.01 | — |
| ARGX | ARGENX SE | $50.94B | $819.14 | — |
| RVMD | Revolution Medicines, Inc. | $38.14B | $177.96 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.